Focusing on England, these two presentations describe the core economic considerations in making the most of targeted therapy. OHE’s Adrian Towse participated in a two-day workshop convened by the Biotherapy Development Association to discuss the process and problems that surround…
Focusing on England, these two presentations describe the core economic considerations in making the most of targeted therapy.
OHE’s Adrian Towse participated in a two-day workshop convened by the Biotherapy Development Association to discuss the process and problems that surround decisions about pricing and reimbursement for innovative oncology medicines in Europe.
OHE’s Adrian Towse participated in a two-day workshop convened by the Biotherapy Development Association to discuss the process and problems that surround decisions about pricing and reimbursement for innovative oncology medicines in Europe. His presentation, below, focused on the situation in England, including the context and current status of pricing and reimbursement decisions, issues that are peculiar to England’s approach, and others that are common across countries, including those just gaining attention. The latter principally include HTA for companion diagnostics, which can improve both the efficiency and effectiveness of cancer therapies, and pricing by indication rather than adopting a single price for all of a medicine’s uses.
Personalised medicine holds great promised for both improving patients’ outcomes and enhancing the economic efficiency of treatment. Medicines paired with diagnostics are the backbone of personalised medicine, presenting new challenges for health technology assessment. The situation in England, particularly how NICE might respond to this challenge, was the focus of the third networking event co-sponsored by the Association of the British Pharmaceutical Industry (ABPI) and the British In Vitro Diagnostics Association (BIVDA). At this one-day event, speakers set the stage for discussion by describing the context of this challenge for England.
OHE’s Adrian Towse presented on how economic concerns affect development of and access to stratified medicine. He discussed the elements of value of diagnostic tests (see our earlier blog post), and described the conditions needed to both foster useful assessments and ensure subsequent use in the marketplace. His topics included issues of evidence generation, incentives for innovation, the need for flexible approaches to ensuring patients’ access coincident with evidence development, and encouraging uptake and use.
OHE remains at the forefront of efforts to develop workable approaches to ensuring the best use and continuing development of personalised medicine. For a summary of recent activities, please click here.
An error has occurred, please try again later.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!